Introduction: Breast cancer is the second most common cancer developing in women worldwide Triple Negative Breast Carcinomas (TNBC) are regarded as one of the most malignant phenotypes, Immunohisto-chemically these tumors are endocrine receptor negative, HER2 -receptor negative, with expression of basal markers -Cytokeratin 5 /6, carrying a poor prognosis. Effective evaluation of these tumor markers helps in efficient treatment of the patient with all these markers carrying a prognostic significance. The current study helps in identifying Cytokeratin 5/6 as a potential multifaceted biomarker and in identifying novel therapeutic agents for Triple Negative Breast Carcinomas. Materials and Methods:The present immunohistochemical study was conducted on 40 histologically proven cases of triple negative breast carcinoma (TNBC) which were further subjected to Cytokeratin 5/6 expression to determine prognostic and therapeutic value. Result: Cytokeratin 5/6 expression was seen in 16 cases of TNBC, out of 40 histologically proven cases of TNBC. The maximum number of patients of triple negative breast carcinoma were in the age group of 41-50 years comprising 40% of the total cases. % of the total cases. Maximum number of cases of triple negative breast carcinoma were of grade III, constituting 60% followed by grade II Conclusion: According to the current study, Cytokeratin 5/6 positivity has got direct relationship with the grade of the tumour, lymph nodal status and lymphovascular invasion in TNBC cases. TNBC have a grave clinical outcome and decreased 5 year survival rate. Thus, it is highlighted that all TNBC patients should be stained by CK 5/6 and if found positive for CK 5/6 expression it, implies basal like phenotype and aggressive intervention is required. Cytokeratin 5/6 carries a diagnostic as wells as therapeutic importance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.